Critical Survey: Precision BioSciences (NASDAQ:DTIL) versus Gain Therapeutics (NASDAQ:GANX)

Precision BioSciences (NASDAQ:DTIL) and Gain Therapeutics (NASDAQ:GANX) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, dividends, valuation and analyst recommendations.

Profitability

This table compares Precision BioSciences and Gain Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Precision BioSciences	-96.73%	-72.52%	-32.25%
Gain Therapeutics	N/A	-161.59%	-118.36%

Volatility and Risk

Precision BioSciences has a beta of 1.24, meaning that its stock price is 24% more volatile than the S&P 500. Comparatively, Gain Therapeutics has a beta of 0.2, meaning that its stock price is 80% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings for Precision BioSciences and Gain Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Precision BioSciences	1	0	4	0	2.60
Gain Therapeutics	1	0	5	0	2.67

Precision BioSciences presently has a consensus price target of $32.25, indicating a potential upside of 383.51%. Gain Therapeutics has a consensus price target of $7.50, indicating a potential upside of 321.35%. Given Precision BioSciences’ higher probable upside, research analysts plainly believe Precision BioSciences is more favorable than Gain Therapeutics.

Valuation and Earnings

This table compares Precision BioSciences and Gain Therapeutics”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Precision BioSciences	$45.05 million	4.09	-$45.72 million	($2.80)	-2.38
Gain Therapeutics	N/A	N/A	-$20.16 million	($0.50)	-3.56

Gain Therapeutics has lower revenue, but higher earnings than Precision BioSciences. Gain Therapeutics is trading at a lower price-to-earnings ratio than Precision BioSciences, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

38.0% of Precision BioSciences shares are owned by institutional investors. Comparatively, 12.0% of Gain Therapeutics shares are owned by institutional investors. 2.7% of Precision BioSciences shares are owned by company insiders. Comparatively, 4.2% of Gain Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Precision BioSciences beats Gain Therapeutics on 7 of the 13 factors compared between the two stocks.

About Precision BioSciences

Precision BioSciences, Inc., an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA. In addition, it develops PBGENE-NVS for sickle cell disease/beta thalassemia for insertion; PBGENE-DMD (excision) for duchenne muscular dystrophy; PBGENE-LL2 (insertion), a liver directed target; PBGENE-LL3, a central nervous system directed target; and iECURE-OTC (insertion) for ornithine transcarbamylase deficiency. The company has license and collaboration agreement with Caribou Biosciences, Inc.; license agreement with TG Cell Therapy, Inc. to develop, manufacture, and commercialize azer-cel for autoimmune diseases and other indications outside of cancer; development and license agreement with Eli Lilly and Company for the research and development of potential in vivo therapies for genetic disorders; Cellectis S.A.; iECURE, Inc. to develop ARCUS-based gene-insertion therapies; Duke University; and Novartis Pharma AG to discover and develop in vivo gene editing products. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.

About Gain Therapeutics

Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. The company's lead drug candidate, GT-02287 for the treatment of GBA1 Parkinson's disease is being evaluated in a Phase I clinical trials. It also has various small molecule drug candidates, which are in the discovery, research, and preclinical stages for the treatment of Dementia with Lewy Bodies, Alzhiemer's Disease, Gaucher, GM1 Gangliosidosis, Krabbe Disease, Alpha1-Antitrypsun deficiency, and solid tumors. Gain Therapeutics, Inc. was founded in 2017 and is headquartered in Bethesda, Maryland.